BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
about
Nintedanib in NSCLC: evidence to date and place in therapyProfile of nintedanib in the treatment of solid tumors: the evidence to dateEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibA high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptorRisk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.Oral epithelial stem cells - implications in normal development and cancer metastasis.Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in ChinaFunctional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.Focus on Nintedanib in NSCLC and Other TumorsSecond-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.Recruitment and retention: factors that affect pericyte migration.miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.Nintedanib in non-small cell lung cancer: from preclinical to approval.Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer.Myocardin-related transcription factors are required for skeletal muscle developmentThe tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.Hypoxia Studies with Pimonidazole in vivo.Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: Contribution to the epithelial-stromal interaction balance.Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis.Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.Cell death-based treatment of lung adenocarcinoma.Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.IGF-1 promotes angiogenesis in endothelial cells/adipose-derived stem cells co-culture system with activation of PI3K/Akt signal pathway.VEGF as a potential target in lung cancer.A multitechnique approach to probe the interaction of a therapeutic tyrosine kinase inhibitor nintedanib and bovine serum albumin.Nintedanib in ovarian cancer.
P2860
Q26745424-902F00D0-3B51-4187-B7BD-FC0FB5E03E7CQ26775134-26227186-73DE-4EEB-A2A8-3C50B309B5DFQ26995204-B2EC99D7-4E68-41AB-8C29-A10DEB53CD4AQ28828478-B4981B6B-C0F5-49D2-8499-0412AD83E641Q30249619-BB9B75CA-D6D9-4F62-8321-798C31571EEDQ30669159-6D8CDBCC-86F9-4B5F-9D22-4F98C0B10D9EQ33563488-668F7B9F-2CB3-4151-BECF-34830F1D5E3BQ33789403-319971DC-01C6-4BA1-88E5-96BE098BCC95Q34147649-FCB65241-E7EF-45B7-B36B-29810CDFAAE5Q35670576-17058A38-4BF9-46D7-9334-CCF90727A7E0Q35796826-E5BE1FAA-3907-47CA-A447-FDE48842FEC3Q35947903-24920CCC-5E63-4CEB-88DE-72C7C9A4F479Q36309451-E4847749-A1C0-4525-AC39-595F53687F78Q36355885-D891CEDF-C494-48E2-BE35-144594ADC831Q36910309-365B336E-A582-4D6B-99D9-EC82DA0CE2E1Q37512962-EEF22528-EB25-4AD8-A7FE-9F329677CCF0Q37670497-4F95E2BE-FA33-4BF5-920A-7CB6D4416741Q38126398-E3F99375-A4F8-4522-A830-052FB48FE618Q38366840-175C8F6F-C563-434E-B0AD-CB2C45AEA437Q38412048-640FAFE9-F284-47D3-8A40-19D7F6BF24C3Q38430583-28453243-7DB0-469A-8E2C-3D190BE7C4E7Q38461691-7925C539-EF8D-4726-A154-B5C5766218D6Q38525073-CA6D1A40-E3B7-427B-88C9-ADE884C479EEQ38650120-04E8BA9B-7C25-49A6-8809-BAADE5A9A30EQ38794338-F943DF23-4060-4913-845E-0D2B15C7999FQ39042485-1774AF88-6D44-4683-8A31-72ED92E042DFQ39839324-87F9F501-EE5E-4EFD-8941-2E455EF6949EQ40975816-EA886B4B-951A-4331-8E01-C4B1CD5562BBQ41583233-7834A38E-BCE2-49B6-8D35-4994A1B7BD30Q42408877-FBCB2A75-9D5A-462E-9190-A5F4055AE918Q42516349-7CC04DE5-8D54-4096-993B-3157A17F86B1Q42804790-919A1190-FAA8-43B8-8444-BE48A7E0B1B0Q43158982-EED41DC0-6C44-4C51-8FCB-21E843467B58Q47230780-4B95462E-7144-4A9B-BB25-F4CF2C315D3EQ47711273-5FEEA850-B169-4906-8734-3B8AD6CAD894Q47719824-5650F634-CAB9-421D-BF7D-72551104D418Q47727030-219F3A35-13D4-43EE-B1AC-BAB58E20C9A2Q47918409-5DE91260-44C9-477A-B99D-D99CB4BD067CQ48024140-4144DFB3-925F-42A5-96D3-AA0CBB6DCE7BQ51824301-F56D2E8F-04E7-420D-AFFF-456C2941F60F
P2860
BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
BIBF 1120 (nintedanib), a trip ...... of lung and pancreatic cancer.
@en
type
label
BIBF 1120 (nintedanib), a trip ...... of lung and pancreatic cancer.
@en
prefLabel
BIBF 1120 (nintedanib), a trip ...... of lung and pancreatic cancer.
@en
P2093
P2860
P1476
BIBF 1120 (nintedanib), a trip ...... of lung and pancreatic cancer
@en
P2093
Bercin Kutluk Cenik
Katherine T Ostapoff
Rolf A Brekken
P2860
P304
P356
10.1158/1535-7163.MCT-12-0995
P577
2013-05-31T00:00:00Z